Cartesian Therapeutics, Inc. Income Statement
RNAC|8 years of annual SEC 10-K data (FY2016-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Cartesian Therapeutics, Inc. reported $39M in revenue and $77M in net loss for FY2025. Revenue has grown at a 32.7% compound annual rate over the past 9 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.9M | $26.0M | $85.1M | $16.6M | $6.7M | $903.0K | $207.0K | $3.0M |
| SG&A Expense | $30.1M | $40.5M | $20.9M | $18.9M | $16.4M | $18.2M | $18.8M | $8.0M |
| R&D Expense | $45.1M | $71.3M | $68.7M | $54.5M | $42.7M | $47.7M | $45.2M | $10.5M |
| Operating Income | -$43.9M | -$86.4M | -$4.6M | -$56.8M | -$52.5M | -$65.0M | -$63.8M | -$15.4M |
| Interest Expense | - | $2.1M | $2.8M | $1.6M | $1.5M | $1.5M | $1.2M | $552.0K |
| Income Tax | $287.0K | -$19.0M | $16.0M | $0 | $0 | - | - | - |
| Net Income | -$77.4M | -$219.7M | -$25.7M | -$68.9M | -$55.4M | -$65.3M | -$65.3M | -$12.9M |
| EPS (Basic) | -$4.48 | -$49.76 | -$0.22 | -$0.68 | -$1.22 | - | - | - |
| EPS (Diluted) | -$4.49 | -$49.76 | -$0.22 | -$0.68 | -$1.22 | -$2.92 | -$3.20 | -$7.84 |
| Shares Outstanding | 25.8M | 5.4M | 153.0M | 123.6M | 108.1M | 86.3M | 22.5M | 2.2M |
| Operating Margin | -112.8% | -332.3% | -5.4% | -342.4% | -785.6% | -7200.7% | -30813.5% | -506.6% |
| Profit Margin | -199.0% | -844.9% | -30.2% | -415.0% | -829.0% | -7235.4% | -31556.0% | -423.7% |